inclusion criteria: 1. female and male patients over the age of 18. 2. confirmed covid-19 infection by pcr analysis 3. hospitalized at soroka university medical center. 4. display mild to moderate symptoms of respiratory infection (temperature \<39.0 oc, respiratory rate \< 25, o2 % sat \> 95% in room air or with supplemental oxygen through nasal cannula, p/f ratio \> 150). 5. willing and able to convey informed consent. 6. willing and able to comply with all study procedures 7. female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication. female patients of childbearing potential are all those except patients who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year postmenopausal. for females: 2 of the following contraceptive methods, with at least 1 being a barrier method: * hormonal contraceptives for ≥ 27 days before dosing * intrauterine device (iud) in place ≥ 27 days before dosing * double-barrier methods (use of condom \[male partner\] with either diaphragm with spermicide or cervical cap with spermicide) from screening * surgical sterilization of the partner (vasectomy ≥ 1 month before screening) female patients must have a negative urine pregnancy test (minimum sensitivity 25 iu/l or equivalent units of human chorionic gonadotropin \[hcg\]) within 24 hours prior to the start of investigational product. for males: * surgical sterilization (vasectomy ≥ 1 month before screening) or * both of the following contraceptive methods from screening: * consistently and correctly use a condom * partner must use a hormonal contraceptive or a nonhormonal barrier method (iud or diaphragm with spermicide or cervical cap with spermicide).

inclusion criteria: 1. female and male patients over the age of 18. 2. confirmed covid-19 infection by pcr analysis 3. hospitalized at soroka university medical center. 4. display mild to moderate symptoms of respiratory infection (temperature \<39.0 oc, respiratory rate \< 25, o2 % sat \> 95% in room air or with supplemental oxygen through nasal cannula, p/f ratio \> 150). 5. willing and able to convey informed consent. 6. willing and able to comply with all study procedures 7. female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication. female patients of childbearing potential are all those except patients who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year postmenopausal. for females: 2 of the following contraceptive methods, with at least 1 being a barrier method: * hormonal contraceptives for ≥ 27 days before dosing * intrauterine device (iud) in place ≥ 27 days before dosing * double-barrier methods (use of condom \[male partner\] with either diaphragm with spermicide or cervical cap with spermicide) from screening * surgical sterilization of the partner (vasectomy ≥ 1 month before screening) female patients must have a negative urine pregnancy test (minimum sensitivity 25 iu/l or equivalent units of human chorionic gonadotropin \[hcg\]) within 24 hours prior to the start of investigational product. for males: * surgical sterilization (vasectomy ≥ 1 month before screening) or * both of the following contraceptive methods from screening: * consistently and correctly use a condom * partner must use a hormonal contraceptive or a nonhormonal barrier method (iud or diaphragm with spermicide or cervical cap with spermicide).

inclusion criteria: female and male patients over the age of 18. confirmed covid-19 infection by pcr analysis hospitalized at soroka university medical center. display mild to moderate symptoms of respiratory infection (temperature <39.0 oc, respiratory rate < 25, o2 % sat > 95% in room air or with supplemental oxygen through nasal cannula, p/f ratio > 150). willing and able to convey informed consent. willing and able to comply with all study procedures female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication. female patients of childbearing potential are all those except patients who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year postmenopausal. for females: 2 of the following contraceptive methods, with at least 1 being a barrier method: hormonal contraceptives for ≥ 27 days before dosing intrauterine device (iud) in place ≥ 27 days before dosing double-barrier methods (use of condom [male partner] with either diaphragm with spermicide or cervical cap with spermicide) from screening surgical sterilization of the partner (vasectomy ≥ 1 month before screening) female patients must have a negative urine pregnancy test (minimum sensitivity 25 iu/l or equivalent units of human chorionic gonadotropin [hcg]) within 24 hours prior to the start of investigational product. for males: surgical sterilization (vasectomy ≥ 1 month before screening) or both of the following contraceptive methods from screening: consistently and correctly use a condom partner must use a hormonal contraceptive or a nonhormonal barrier method (iud or diaphragm with spermicide or cervical cap with spermicide).

inclusion criteria: female and male patients over the age of 18. confirmed covid-19 infection by pcr analysis hospitalized at soroka university medical center. display mild to moderate symptoms of respiratory infection (temperature <39.0 oc, respiratory rate < 25, o2 % sat > 95% in room air or with supplemental oxygen through nasal cannula, p/f ratio > 150). willing and able to convey informed consent. willing and able to comply with all study procedures female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication. female patients of childbearing potential are all those except patients who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year postmenopausal. for females: 2 of the following contraceptive methods, with at least 1 being a barrier method: hormonal contraceptives for ≥ 27 days before dosing intrauterine device (iud) in place ≥ 27 days before dosing double-barrier methods (use of condom [male partner] with either diaphragm with spermicide or cervical cap with spermicide) from screening surgical sterilization of the partner (vasectomy ≥ 1 month before screening) female patients must have a negative urine pregnancy test (minimum sensitivity 25 iu/l or equivalent units of human chorionic gonadotropin [hcg]) within 24 hours prior to the start of investigational product. for males: surgical sterilization (vasectomy ≥ 1 month before screening) or both of the following contraceptive methods from screening: consistently and correctly use a condom partner must use a hormonal contraceptive or a nonhormonal barrier method (iud or diaphragm with spermicide or cervical cap with spermicide).

inclusion criteria: 1. female and male patients over the age of 18. 2. confirmed covid-19 infection by pcr analysis 3. hospitalized at soroka university medical center. 4. display mild to moderate symptoms of respiratory infection (temperature <39.0 oc, respiratory rate < 25, o2 % sat > 95% in room air or with supplemental oxygen through nasal cannula, p/f ratio > 150). 5. willing and able to convey informed consent. 6. willing and able to comply with all study procedures 7. female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication. female patients of childbearing potential are all those except patients who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year postmenopausal. for females: 2 of the following contraceptive methods, with at least 1 being a barrier method: - hormonal contraceptives for ≥ 27 days before dosing - intrauterine device (iud) in place ≥ 27 days before dosing - double-barrier methods (use of condom [male partner] with either diaphragm with spermicide or cervical cap with spermicide) from screening - surgical sterilization of the partner (vasectomy ≥ 1 month before screening) female patients must have a negative urine pregnancy test (minimum sensitivity 25 iu/l or equivalent units of human chorionic gonadotropin [hcg]) within 24 hours prior to the start of investigational product. for males: - surgical sterilization (vasectomy ≥ 1 month before screening) or - both of the following contraceptive methods from screening: - consistently and correctly use a condom - partner must use a hormonal contraceptive or a nonhormonal barrier method (iud or diaphragm with spermicide or cervical cap with spermicide).

inclusion criteria: 1. female and male patients over the age of 18. 2. confirmed covid-19 infection by pcr analysis 3. hospitalized at soroka university medical center. 4. display mild to moderate symptoms of respiratory infection (temperature <39.0 oc, respiratory rate < 25, o2 % sat > 95% in room air or with supplemental oxygen through nasal cannula, p/f ratio > 150). 5. willing and able to convey informed consent. 6. willing and able to comply with all study procedures 7. female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication. female patients of childbearing potential are all those except patients who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year postmenopausal. for females: 2 of the following contraceptive methods, with at least 1 being a barrier method: - hormonal contraceptives for ≥ 27 days before dosing - intrauterine device (iud) in place ≥ 27 days before dosing - double-barrier methods (use of condom [male partner] with either diaphragm with spermicide or cervical cap with spermicide) from screening - surgical sterilization of the partner (vasectomy ≥ 1 month before screening) female patients must have a negative urine pregnancy test (minimum sensitivity 25 iu/l or equivalent units of human chorionic gonadotropin [hcg]) within 24 hours prior to the start of investigational product. for males: - surgical sterilization (vasectomy ≥ 1 month before screening) or - both of the following contraceptive methods from screening: - consistently and correctly use a condom - partner must use a hormonal contraceptive or a nonhormonal barrier method (iud or diaphragm with spermicide or cervical cap with spermicide).